Effect of Acute Intake of Meals Containing Higher vs. Lower Energy From Protein on DIT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-08

Study Completion Date

2024-11-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to assess the effects of acute intake of mixed meals containing higher vs. lower energy from protein on diet induced thermogenesis (DIT) in adults with overweight or obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women

NCT00912210

Bone and Body Composition Obesity Metabolic Syndrome +2 more

COMPLETED PHASE1

Effects of High Protein Intake With Intense Exercise and Energy Deficit

NCT01776359

Overweight

COMPLETED NA

Whey Protein Micelles and Thermogenesis in Overweight Subjects

NCT02303080

Overweight

COMPLETED NA

Protein Supplementation and HIIT: Impact on Cardiorespiratory Fitness

NCT04359342

Primary Prevention Health Promotion

UNKNOWN NA

The Effect of Very Low Calorie Diet With and Without Exercise on Muscle Synthesis in Middle-aged Overweight Male.

NCT03116256

Overweight and Obesity

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Overweight and Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Higher protein

Group Type EXPERIMENTAL

Higher protein

Intervention Type OTHER

An acute mixed meal containing higher protein

Lower protein

Group Type ACTIVE_COMPARATOR

Lower protein

Intervention Type OTHER

An acute mixed meal containing lower protein

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Higher protein

An acute mixed meal containing higher protein

Intervention Type OTHER

Lower protein

An acute mixed meal containing lower protein

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female 18 to 55 years of age, inclusive. There will be approximately equal numbers of men and women within the groups with overweight/obesity and normal weight.
2. Individual has BMI of 18.5 to 24.9 kg/m2 or 27.0 to 34.9 kg/m2, inclusive.
3. Individual has a REE (measured at the screening visit using indirect calorimetry) between 1,250 and 2,250 kcals/d.
4. For premenopausal women, individual has a history of regular menstrual cycles (21-35 d per cycle) for at least 3 months prior to visit 1.
5. Individual is judged by the Investigator to be in generally good health on the basis of medical history and screening measurements.
6. Individual is willing and able to undergo the scheduled study procedures.
7. Individual understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion Criteria

1. Individual has a laboratory test result of clinical significance based on the judgment of the Principal Investigator or qualified designee.
2. Individual has a clinically significant medical condition that, in the opinion of the Investigator, could interfere with the interpretation of the study results. Health conditions may include history or presence of clinically important cardiac, renal, hepatic, endocrine (i.e., diabetes), pulmonary, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Investigator.
3. Use of tobacco/nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1.
4. Use of hemp/marijuana products within 12 months of visit 1. Occasional use (e.g., once or twice a month) within 12 months of visit 1 is allowed but requires at least a 14-d washout prior to visit 1 and the participant must be willing to refrain from use during the study.
5. Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg) at screening.
6. Individual has used an alpha-blocker, beta-blocker, or high-dose diuretic within 30 d of visit 1. Unstable use (initiation or change in dose) within 30 d of visit 1 of other antihypertensive medications is also exclusionary.
7. Unstable use (initiation or change in dose) within 30 d of visit 1 of thyroid hormone replacement medications.
8. Unstable use (initiation or change in dose) within 30 d of visit 1 of sex hormones for contraception.
9. Use of medications or supplements that may influence carbohydrate or fat metabolism, including but not limited to hypoglycemic medications and systemic (intravenous, intramuscular, or oral) or ≥1500 µg/d (topical, inhaled, intranasal, or dermal) corticosteroids within 30 d of visit 1.
10. Use of any weight loss medication within 90 d of visit 1.
11. Use of medications or supplements that may influence heart rate, including but not limited to stimulant medications (e.g., amphetamines, methylphenidates, etc.) within 30 d of visit 1.
12. Individual has a history of cancer in the prior 5 years, except non-melanoma skin cancer or carcinoma in situ of the cervix.
13. Individual has had a weight change of ± 4.5 kg (10 lbs) in the previous 3 months.
14. Individual has extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian).
15. Individual is actively following a weight loss diet (even if maintaining body weight).
16. Individual habitually consumes a diet with \<10% or ≥ 20% of energy from protein.
17. Individual regularly consumes (≥ 2 times per week) protein supplements (wash out is permitted).
18. Individual has a history of bariatric surgery or is actively attempting to lose or gain body weight.
19. History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
20. History of any major trauma or major surgical event within 2 months of visit 1.
21. Individual has signs or symptoms of an active infection of clinical significance or has taken antibiotics within 5 days prior to any visit (washout is permitted for re-scheduling of the clinic visit).
22. Individual has an allergy, sensitivity or intolerance to any components of the study meals.
23. Individual is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
24. Individual has been exposed to any non-registered drug product within 30 days prior to screening.
25. Individual has a current or recent history (within 12 months prior to screening) or strong potential for illicit drug or excessive alcohol intake defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).
26. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes